Neurobiology and pharmacology of a new antidepressant therapy;Basi neurobiologiche e farmacologiche di una innovativa terapia antidepressiva

Italian Journal of Psychopathology

Volumn 17, Issue 3, 2011, Pages 335-340

  Biggio, Giovanni ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Depression; Neuronal plasticity; New drugs

Indexed keywords

AGOMELATINE; DOPAMINE; MONOAMINE; NORADRENALIN; SEROTONIN 2C AGONIST;

AFFECT; ARTICLE; BRAIN LEVEL; CIRCADIAN RHYTHM; COGNITION; CONCENTRATION (PARAMETERS); DEPRESSION; DISEASE SEVERITY; EMOTION; HUMAN; MAJOR DEPRESSION; NERVE ENDING; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; PREFRONTAL CORTEX; SYNAPSE; SYNTHESIS;

EID: 80855129214     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008;358:55-68.
2. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:137-51. (Pubitemid 43151600)
3. de Bodinat C, Guardiola-Lemaitre B, Mocaër E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010;9:628-42.
4. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005;10:732-47. (Pubitemid 41443048)
5. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008;455:894-902.
6. Banasr M, Soumier A, Hery M, et al. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006;59:1087-96. (Pubitemid 43849657)
7. Racagni G, Riva MA, Popoli M. The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol 2007;22(Suppl 2):S9-S14. (Pubitemid 47530848)
8. Païzanis E, Renoir T, Lelievre V, et al. Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice. Int J Neuropsychopharmacol 2010;13:759-74.
9. Soumier A, Banasr M, Lortet S, et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology 2009;34:2390-403.
10. Li CT, Lin CP, Chou KH, et al. Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study. Neuroimage 2010;50:347-56.
11. Campbell S, Marriott M, Nahmias C, et al. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 2004;161:598-607. (Pubitemid 38445502)
12. De Carol is NA, Eisch AJ. Hippocampal neurogenesis as a target for the treatment of mental illness: a critical evaluation. Neuropharmacology 2010;58:884-93.
13. Ramírez-Rodríguez G, Klempin F, Babu H, et al. Melatonin modulates cell survival of new neurons in the hippocampus of adult mice. Neuropsychopharmacology 2009;34:2180-91.
14. Manda K, Reiter RJ. Melatonin maintains adult hippocampal neurogenesis and cognitive functions after irradiation. Prog Neurobiol 2010;90:60-8.
15. Nutt D, Demyttenaere K, Janka Z, et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure. J Psychopharmacol 2007;21:461-71. (Pubitemid 47106935)
16. Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 2009;10:211-23.
17. Keedwell PA, Andrew C, Williams SC, et al. The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry 2005;58:843-53. (Pubitemid 41790711)
18. Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006;67:865-73. (Pubitemid 44049084)